Recent clinical trials for pediatric low-risk Hodgkin lymphoma
| Study . | N . | Risk group . | Rx . | Radiation (Gy) . | Directly assigned to radiation, % . | EFS or DFS, %; OS, % (y) . |
|---|---|---|---|---|---|---|
| Children’s Oncology Group | ||||||
| CCG59424 | 215 | IA, IB, IIA without adverse features* | COPP/ABV ×4 | CR after cycle 4: randomized to 21, IF | 23% of overall study population (not restricted to low risk) | IF: 97.1 None: 89.1 (p = .001); |
| POG94265 | 294 | IA, IIA, IIIA (no bulk) | DBVE ×2-4 (based on response after cycle 2) | vs none; PR: 21, IF 25.5, IF | 100 | IF: 100 None: 95.9 (p = 0.5) (10) 86.2; 97.4 (8) |
| AHOD04316 | 287 | IA, IIA (no bulk) | AVPC ×3 | CR after cycle 3: none PR: 21, IF | 37 | 79.8; 99.6 (4) |
| German Society of Pediatric Oncology | ||||||
| GPOH7 | 195 | IA, IB, IIA | OEPA (males) | CR after cycle 2: no RT; PR after cycle 2: 20-30, IF | 70 | 92; 99.5 (5) |
| OPPA (females) ×2 | ||||||
| French Society of Pediatric Oncology (SFOP) | ||||||
| MDH-908 | 202 | IA, IB, IIA, IIB | VBVP ×4 (*OPPA ×1-2 if PR after cycle 4) | 20-40, IF | 100 | 91.1, 97.5 (5) |
| Stanford, Dana Farber and St Jude Consortium | ||||||
| Stanford, Dana Farber, and St Jude Consortium9 | 110 | IA, IB, IIA, IIB no bulk, no E | VAMP ×4 | 15-22.5, IF | 100 | 89.4; 96.1 (10) |
| Stanford, Dana Farber, and St Jude Consortium17 | 88 | IA, IIA, <3 nodal sites, no bulk, no E | VAMP ×4 | CR after 2 cycles: no RT; PR after cycle 2: 25.5 IF | 47 | CR: 89.4; PR: 92.5 (2) |
| Study . | N . | Risk group . | Rx . | Radiation (Gy) . | Directly assigned to radiation, % . | EFS or DFS, %; OS, % (y) . |
|---|---|---|---|---|---|---|
| Children’s Oncology Group | ||||||
| CCG59424 | 215 | IA, IB, IIA without adverse features* | COPP/ABV ×4 | CR after cycle 4: randomized to 21, IF | 23% of overall study population (not restricted to low risk) | IF: 97.1 None: 89.1 (p = .001); |
| POG94265 | 294 | IA, IIA, IIIA (no bulk) | DBVE ×2-4 (based on response after cycle 2) | vs none; PR: 21, IF 25.5, IF | 100 | IF: 100 None: 95.9 (p = 0.5) (10) 86.2; 97.4 (8) |
| AHOD04316 | 287 | IA, IIA (no bulk) | AVPC ×3 | CR after cycle 3: none PR: 21, IF | 37 | 79.8; 99.6 (4) |
| German Society of Pediatric Oncology | ||||||
| GPOH7 | 195 | IA, IB, IIA | OEPA (males) | CR after cycle 2: no RT; PR after cycle 2: 20-30, IF | 70 | 92; 99.5 (5) |
| OPPA (females) ×2 | ||||||
| French Society of Pediatric Oncology (SFOP) | ||||||
| MDH-908 | 202 | IA, IB, IIA, IIB | VBVP ×4 (*OPPA ×1-2 if PR after cycle 4) | 20-40, IF | 100 | 91.1, 97.5 (5) |
| Stanford, Dana Farber and St Jude Consortium | ||||||
| Stanford, Dana Farber, and St Jude Consortium9 | 110 | IA, IB, IIA, IIB no bulk, no E | VAMP ×4 | 15-22.5, IF | 100 | 89.4; 96.1 (10) |
| Stanford, Dana Farber, and St Jude Consortium17 | 88 | IA, IIA, <3 nodal sites, no bulk, no E | VAMP ×4 | CR after 2 cycles: no RT; PR after cycle 2: 25.5 IF | 47 | CR: 89.4; PR: 92.5 (2) |
VBVP indicates vinblastine, bleomycin, etoposide, prednisone; VAMP, vinblastine, doxorubicin, methotrexate, prednisone; COPP/ABV, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine; DBVE, doxorubicin, bleomycin, vincristine and etoposide; OEPA, vincristine, etoposide, prednisone, doxorubicin; OPPA, vincristine, prednisone, procarbazine, doxorubicin; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine; DECA, dexamethasone, etoposide, cisplatin, cytarabine; SFOP, French Pediatric Oncology Society; CCG, Children’s Cancer Study Group; COG, Children’s Oncology Group; GPOH, German Society of Pediatric Oncology and Hematology; POG, Pediatric Oncology Group; IF, involved field; RER, rapid early responder; and SER, slow early responder.
Adverse features: hilar disease, bulk, ≥4 nodal regions, mediastinal bulk.